Cooperative Agreement UH2CA308227
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $279K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New Haven, CT 06510, USA
Similar Awards
- The National Cancer Institute awarded Yale University $677,621 on May 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a blood test for early detection of non-Hodgkin's lymphoma in people with HIV. The research measures altered methylation patterns of tumor-derived cell-free DNA fragments in blood as biomarkers of lymphomagenesis, specifically evaluating hypermethylation of Epstein-Barr virus DNA and gene promoters in infected B cell genomes that arise...
- The National Cancer Institute awarded Raiz Diagnostics, Inc. $4.06 million on September 17, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance LymphomaDx, a gene expression diagnostic assay for lymphoma identification and subtyping. LymphomaDx combines chemical ligation probe amplification with a locked machine learning algorithm to diagnose lymphoma from formalin-fixed, paraffin-embedded core needle biopsies without pathology morphology review, delivering...
- The National Institutes of Health National Cancer Institute awarded The Leland Stanford Junior University $638,972 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated liquid biopsy framework for noninvasive characterization of peripheral T-cell lymphomas. The funded research integrates circulating cell-free DNA and cell-free RNA analysis to detect minimal residual disease, monitor disease dynamics, improve disease classification,...
- Cooperative Agreement Award Summary Yale University received a $251,360 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop and validate multiplexed quantitative immunofluorescence (MQIF) assays for improved patient stratification in cancer immunotherapy and PARP inhibitor treatments. The award, effective September 1, 2025, through August 31, 2027, addresses the unmet clinical need for predictive biomarkers...
- The National Cancer Institute awarded a cooperative agreement totaling $738,675 to Beckman Research Institute of the City of Hope on March 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an exosome-based liquid biopsy assay for non-invasive early detection of colorectal adenomas and cancers. The project addresses the limitation that current fecal immunochemical testing (FIT) shows declining sensitivity for early-stage colorectal cancer and advanced...
- The National Cancer Institute awarded New York University $703,227 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an ultra-rapid droplet digital PCR method for real-time molecular profiling of cancer-driving mutations during surgical resection. The funded work aims to engineer a microfluidic device that automates ultra-rapid DNA extraction and PCR thermal cycling to profile tissue samples in minutes rather than hours, enabling surgeons to...
- The National Cancer Institute awarded Rutgers, The State University of New Jersey, School of Nursing $239,352 on August 11, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a sequencing-free PCR-based method for deep T-cell receptor profiling using sloppy molecular beacons in single-cell droplet digital PCR. The recipient will deliver a diagnostic technique that identifies T-cell receptor variable gene segment usage while preserving alpha-beta chain...
- The National Cancer Institute awarded Mayo Clinic $565,423 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate individualized DNA junction-based liquid biopsies for monitoring glioblastoma and high-grade gliomas during and after treatment. The research addresses a clinical gap in glioma surveillance. Current magnetic resonance imaging monitoring using RANO 2.0 criteria lacks sensitivity and specificity for detecting early disease...
- The National Cancer Institute awarded The Johns Hopkins University $645,435 on September 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a multimodal blood-based classifier for early hepatocellular carcinoma (HCC) detection. The research integrates genome-wide methods—fragmentomics (DELFI), repeat landscapes (ARTEMIS), methylomics, mutational signatures (GEMINI), and plasma proteomics—into a single machine learning classifier to improve HCC...
- The National Cancer Institute awarded Yale University $607,690 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an MR-based platform for simultaneous intracellular pH (PHI) and extracellular pH (PHE) imaging in glioblastoma multiforme (GBM). The research aims to distinguish glycolytic and oxidative tumor phenotypes by measuring transmembrane pH gradients, which are larger in tumors than normal tissue and vary between metabolic phenotypes....